珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
RAD 2025: Long-Term Data on Nemluvio (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to T
2025年06月10日 00:54:09来源:作者:
【摘要】 New interim two-year data from a long-term extension study of Nemluvio in atopic dermatitis reinforce its rapid onset of action and demonstrate its lasting impact across multiple clinical and patient reported outcomes including itch and ski

New interim two-year data from a long-term extension study of Nemluvio in atopic dermatitis reinforce its rapid onset of action and demonstrate its lasting impact across multiple clinical and patient reported outcomes including itch and skin lesions1
Results build on data from the phase III ARCADIA program, showing Nemluvio’s consistent safety profile and sustained and increased improvements in efficacy outcomes in atopic dermatitis patients during prolonged treatment up to two years1,2
Two-year data from a long-term extension study of Nemluvio in prurigo nodularis will also be presented later in June at the International Congress of Dermatology

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis. The data show that Nemluvio is well tolerated, with no new safety signals identified, reinforcing its rapid onset of action and demonstrating sustained and increased improvements in symptoms including itch and skin lesions with prolonged treatment up to two years.1 These data will be presented in a late-breaker abstract at the Revolutionizing Atopic Dermatitis (RAD) Conference, taking place from June 6-7, 2025.

 

“With Nemluvio now being launched in several countries, it’s so encouraging that we continue to see its robust evidence base expand. Long-term data is pivotal to this, highlighting the profound impact this innovative treatment can have in atopic dermatitis well into the future.”
 

BALDO SCASSELLATI SFORZOLINI, M.D., PHD.

GLOBAL HEAD OF RESEARCH & DEVELOPMENT

GALDERMA

 

 

 

责任编辑: admin

看新闻,关注新闻

本网网友:Alexandr 嫁衣°
评论:泰坦尼克号选在2012上映是要告诉我们,作为屌丝,就算你搞到了船票,也是死路一条。

天猫网友:记得牵绊的人
评论:人生没有彩排,每天都是直播;不仅收视率低,而且工资不高。

凤凰网友:执念/173yeah°
评论:每个人出生时都是原创的,但可悲的是,很多人渐渐活成了盗版的。

腾讯网友:m/m  撕心裂肺°
评论:人=吃饭+睡觉+上班+玩,猪=吃饭+睡觉 ∴人=猪+上班+玩 ∴人-玩=猪+上班,不懂玩的人=会上班的猪

搜狐网友:不懂得挽留ゝ
评论:对于男人而言,前女友就好象是亲生的,后女友就像是领养的。

网易网友:听ヽ天甾哭泣
评论:感情之所以惨淡,是通常一个人乞求,另一个人却不施舍

淘宝网友:I.Sshould~寂寞
评论:警察说:"你不知道开车不让打电话吗?"我一脸疑惑的说:"我没打电话呀?.....我发短信来着!"

天涯网友:Sunny°刺眼
评论:老师说过早恋是不好的,我们很听话,只会暗恋

百度网友:圈套  Easuysug▍
评论:我要多念一点书,哪怕以后当流氓,那咱也是有文化的流氓。

猫扑网友: ≈   碎花
评论:坐地铁,是一项糅合太极,柔道,缩骨功的综合性运动。

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!